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Abstract
Background: TP53 is frequently mutated across various tissue types of cancers. In normal cells, long interspersed
nuclear element-1 (LINE-1, L1) is mostly repressed by DNA methylation in its 5′ untranslated region but is activated
by DNA demethylation process during tumorigenesis. p53 is indispensable for maintaining genomic stability and
plays its role in controlling genomic stability by repressing retrotransposon activity. However, it is unclear whether
p53 regulates expression or methylation of L1 differently depending on the mutational status of TP53. Four hundred
ninety cases of advanced gastric cancer (AGC) were analyzed for their statuses in p53 expression and L1 methylation
using immunohistochemistry and pyrosequencing, respectively. Whether L1 methylation and expression statuses were
differently affected by types of TP53 mutants was analyzed in gastric cancer cell line.
Results: By p53 immunohistochemistry, tumors were classified into 4 groups according to the intensity and extent of
stained tumor nuclei. L1 methylation level was significantly higher in p53 expression group 1 than in the other groups
in which L1 methylation level was similar (P < 0.001). Although L1 methylation and p53 expression statuses were
associated with patient survival, multivariate analysis revealed that L1 methylation was an independent prognostic
parameter. In in vitro analysis of AGS cells with the introduction of wild type or mutant types of TP53, L1 methylation
level and activity were different depending on types of TP53 mutation.
Conclusions: Findings suggest that L1 methylation level is affected by TP53 mutation status; although, L1 methylation
status was an independent prognostic parameter in patients with AGC. Further study is required to elucidate
the mechanism of how wild type or mutant p53 affects L1 activity and methylation status of L1 CpG island.
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Background
Gastric cancer is the fifth most common malignant
tumor and the third leading cause of cancer-related
death worldwide. Despite advances in technology, the
diagnosis and treatment of gastric cancer still remains a
challenge [1]. The current TNM staging serves well for
the selection of treatment and assessment of prognosis.
However, survival time varies in patients with advanced
gastric cancer (AGC) within the same stage, which indi-
cates that the current TNM staging system is not sufficient
for the prognosis estimation. Development of prognostic
biomarkers might ameliorate the prognostication power of
the current staging system.
Long interspersed nuclear element-1 (LINE-1, L1) is a
retrotransposon which is repeated a half million times in
an interspersed manner and comprises about 17% of the
human genome. Promoter CpG island hypermethylation
is an important mechanism for the suppression of gene
expression and retrotransposon activity. Cancer cells
tend to undergo diffuse hypomethylation which leads to
the increased activity of L1 retrotransposon [2, 3]. Hypo-
methylation of L1 may contribute to genomic instability
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and tumorigenesis [4]. DNA hypomethylation in the 5′
untranslated region of L1 repeats has been demonstrated
to be closely associated with worse recurrence-free
survival and overall survival in patients with gastric
cancer [5].
Somatic mutation of the TP53 gene is one of the most
frequent alterations in human cancer [6]. Overall, 50%
of human cancers contains TP53 mutation, and negative
regulators of p53, MDM2 and MDM4, are frequently
increased in remnant cases [7]. In most cases of TP53
mutation, a single amino acid is substituted in the DNA
binding domain, which leads to loss of function despite
the protein length being intact [8, 9]. “Loss of function”
mutation in TP53 means loss of function in the regula-
tion of cell cycle checkpoint and induction of apoptosis
by its protein p53 [10]. In spite of the fact that TP53 is
largely accepted as a tumor suppressor gene, oncogenic
effect of mutant p53 proteins, including deregulated
metabolic pathway, increased tumor invasion, and en-
hanced chemotherapy resistance, has also been reported,
indicating a gain of function role for mutant p53 [10–13].
One of the mechanisms involving gain of function in
TP53 mutation includes upregulation of epigenetic genes,
especially genes that serve as histone methyltransferases
and acetyltransferases, via binding to the transcription
factor. A recent study by Zhu et al. has demonstrated that
MLL1, MLL2, and MOZ were upregulated in human
tumor samples with TP53 gain of function mutations, but
not when TP53 was wild type or null status [9]. However,
the effect of p53 in other epigenetic regulators, including
the promoter methylation status of L1, is still elusive.
To date, it is well established that L1 is hypomethy-
lated in many tissue types of cancer and causes genomic
instability. Also, p53 acts as a guardian against transpo-
sopathy, which maintains genomic stability of the cell by
restraining transposable element such as L1 [14]. How-
ever, the correlation between L1 methylation and p53
expression statuses is largely unknown in human gastric
cancer. Also, it is unclear whether the difference in mu-
tational status of TP53 affects L1 expression or not. In
the present study, we investigated the correlation be-
tween p53 expression and L1 methylation statuses to
determine whether expression status or mutational sta-
tus of TP53 influences expression and methylation status
of L1 in gastric cancer tissues or cell lines.
Results
L1 methylation level and p53 expression statuses in AGC
p53 expression was categorized into four groups accord-
ing to the overall intensity of nuclear staining of tumor
cells and the extent of stained cells. When we compared
L1 methylation levels among four p53 expression
groups, significant differences were noted in L1 methyla-
tion levels among four subgroups (P < 0.001, ANOVA)
(Figure 1a). p53 expression group 1 showed a significantly
higher level of L1 methylation than that of the other three
groups which exhibited similar levels of L1 methylation.
Microsatellite instability (MSI)-negative, Epstein–Barr virus
(EBV)-negative AGCs also had similar results, as group 1
showed the highest L1 methylation level (Fig. 1b). In
MSI-high (MSI-H) and EBV-positive AGC populations,
however, a relatively small number of samples for each
group undermined the correlation between p53 expression
status and L1 methylation level (Fig. 1c & d).
Correlation between L1 methylation level, p53 expression
status, and clinicopathological characteristics
L1 methylation level was significantly associated with
various clinicopathological features as we have previ-
ously reported (Additional file 1: Figure S1) [5, 15]. Sig-
nificantly correlated variables include age, sex, lymphatic
invasion, venous invasion, Lauren’s classification, pN
stage, tumor differentiation, molecular phenotypes, and
MSI-H and EBV-positive AGCs. L1 methylation level
was 77.3, 73.9, and 71.0% in EBV-positive, MSI-H, and
EBV-negative/MSI-negative AGCs, respectively. A sig-
nificant difference was noted in L1 methylation levels
between MSI-H and MSI-negative/EBV-negative AGCs
(P < 0.001, Student t test) and between EBV-positive
and MSI-H AGCs (P < 0.001, Student t test). Correl-
ation between p53 expression and clinicopathological
characteristics was measured with two different classifi-
cation schemes (Table 1). When associations between
p53 expression subgroups and clinicopathological fea-
tures were analyzed, significant associations were found
in lymphatic invasion, venous invasion, and MSI and
EBV status (P < 0.05). Since p53 expression group 1 was
contrasted with the other expression groups in terms of
L1 methylation level, we compared clinicopathological
features between group 1 and the other three groups
(group 0, 2, and 3). Group 1 was associated with poor
tumor differentiation (P < 0.05) but had less lymph node
metastasis compared with the other three groups (P =
0.008). Moreover, local invasions including lymphatic in-
vasion and venous invasion were much less frequent in
group 1 (P < 0.001 and P = 0.034, respectively). MSI-H
and EBV-positive subtypes were more frequently ob-
served in group 1 than in all other groups combined
(P < 0.001 and P = 0.005, respectively).
Survival analysis
In previous studies [5, 15], we have found that tumoral
L1 hypomethylation is a biomarker associated with poor
prognosis. However, the effect of p53 has not been con-
sidered as a covariate in these attempts. Therefore, we
further explored the prognostic implication of L1 methy-
lation with the addition of p53 expression status. L1
methylation status was classified into low and high as
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previously described [15]. In univariate survival analysis,
p53 group 1 showed prolonged overall survival (OS)
and disease-free survival (DFS) when compared with
the respective one of p53 group 0 (P = 0.037 and P =
0.018, respectively; Fig. 2a). When p53 group 1 was
compared with all other groups combined, p53 group 1
exhibited marginally better OS than all other p53
groups (P = 0.052, Fig. 2b). p53 group 1 also had a fa-
vorable prognosis for DFS compared with all other p53
groups (P = 0.030). Multivariate analysis reveals that L1
methylation level, lymphatic invasion, and pTNM stage
were independent prognostic factors in OS and DFS.
On the other hand, p53 expression status was not a
prognostic factor when adjusted for pTNM stage,
lymphatic invasion, venous invasion, perineural inva-
sion, and L1 methylation level (Table 2). Also, we ana-
lyzed patient survival according to L1 methylation
status in each p53 subset (Fig. 3). These findings con-
firmed that L1 methylation level was a superior prog-
nostic marker in AGC. However, we clearly identified
the potential interaction between p53 expression and
L1 methylation (Fig. 1). From these findings, we de-
cided to investigate the interaction of p53 expression
and L1 methylation in vitro.
In vitro study demonstrating variation of L1 methylation
level according to p53 mutation status
Gastric cancer cell line AGS was found to be wild type
TP53 alleles (http://www.cbioportal.org). AGS cells were
transfected with pLRE3-mEGFP1 (wild type L1 plasmid)
and then knocked down with TP53 shRNA to generate
cell status comparable to null mutation of TP53 in terms
of p53 expression status. TP53-knocked down AGS cells
were stably transfected with wild type TP53 or mutant
type TP53 (V143A, R175H, and R249S) (Additional
file 2: Figure S2). We assessed L1 activity by evalu-
ation of EGFP expression since it is difficult to detect
ORF proteins of L1 due to its unconventional translation
mechanism [16, 17]. Therefore, EGFP expression was con-
sidered as a surrogate for L1 expression (Fig. 4). More
EGFP-positive cells were observed in AGS cells trans-
fected with mutant TP53 R175H cells than in AGS cells
transfected with mutant TP53 V143A or R249S, which
was confirmed by western blot of EGFP protein.
Discussion
In our previous studies, L1 methylation level was found to
be a reliable independent prognostic biomarker in which a
low methylation status was associated with worse clinical
Fig. 1 Correlation between p53 expression and L1 methylation level measured by pyrosequencing. a All molecular subtype AGC included. b MSI-
negative, EBV-negative AGC samples, c MSI-High AGC samples, d EBV-positive AGC samples
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Table 1 p53 expression status and its association with clinicopathological features
p53 expression group P value P value
(1 vs 0, 2,
and 3)
0 1 2 3
Sex 0.089 0.074
Male 70 (14.3) 117 (23.9) 66 (13.5) 79 (16.1)
Female 33 (6.7) 69 (14.1) 18 (3.7) 38 (7.8)
Age 0.927 0.809
> 61 46 (9.4) 91 (18.6) 40 (8.2) 58 (11.8)
≤ 61 57 (11.6) 95 (19.4) 44 (9.0) 59 (12.0)
Tumor differentiation 0.174 0.008
Well 2 (0.4) 5 (1.0) 0 (0) 2 (0.4)
Moderate 27 (5.5) 38 (7.8) 27 (5.5) 32 (6.5)
Poor 18 (3.7) 72 (14.7) 30 (6.1) 31 (6.3)
Poorly cohesive 35 (7.1) 53 (10.8) 15 (3.1) 39 (8.0)
Others 21 (4.3) 18 (3.7) 12 (2.4) 13 (2.7)
Lauren classification 0.168 0.052
Intestinal 48 (9.8) 58 (5.9) 32 (6.5) 46 (9.4)
Diffuse 44 (9.0) 99 (11.8) 36 (7.3) 56 (11.4)
Mixed 11 (2.2) 29 (5.9) 16 (3.3) 15 (3.1)
pT 0.704 0.390
pT2 26 (5.3) 44 (9) 18 (3.7) 26 (5.3)
pT3 38 (7.8) 73 (14.9) 31 (6.3) 39 (8.0)
pT4a 33 (6.7) 63 (12.9) 29 (5.9) 49 (10.0)
pT4b 6 (1.2) 6 (1.2) 6 (1.2) 3 (0.6)
pN 0.056 0.008
pN0 29 (5.9) 72 (14.7) 22 (4.5) 25 (5.1)
pN1 12 (2.4) 34 (6.9) 18 (3.7) 27 (5.5)
pN2 22 (4.5) 30 (6.1) 19 (3.9) 21 (4.3)
pN3a 26 (5.3) 27 (5.5) 18 (3.7) 27 (5.5)
pN3b 14 (2.9) 23 (4.7) 7 (1.4) 17 (3.5)
pTNM 0.407 0.090
IB 16 (3.3) 30 (6.1) 7 (1.4) 10 (2.0)
IIA 13 (2.7) 39 (8.0) 12 (2.4) 16 (3.3)
IIB 11 (2.2) 26 (5.3) 21 (4.3) 24 (4.9)
IIIA 13 (2.7) 27 (5.5) 7 (1.4) 12 (2.4)
IIIB 18 (3.7) 21 (4.3) 14 (2.9) 21 (4.3)
IIIC 18 (3.7) 23 (4.7) 15 (3.1) 22 (4.5)
IV 14 (2.9) 20 (4.1) 8 (1.6) 12 (2.4)
Lymphatic invasion < 0.001 < 0.001
Absent 29 (5.9) 93 (19.0) 27 (5.5) 31 (6.3)
Present 74 (15.1) 93 (19.0) 57 (11.6) 86 (17.6)
Venous invasion 0.028 0.034
Absent 66 (13.5) 149 (30.4) 61 (12.5) 89 (18.2)
Present 37 (7.6) 37 (7.6) 23 (4.7) 28 (5.7)
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outcome of AGC patients (17, 18). In our current investi-
gation, L1 methylation level was different among p53
expression groups which were also associated with OS
and DFS. Despite a strong correlation between L1 methy-
lation level and p53 expression status, tumoral L1 hypo-
methylation was found to be an independent prognostic
parameter in a multivariate analysis incorporating p53
expression status as a covariate. However, p53 expression
status no longer maintained its prognostic implication in
multivariate analysis. Although tumoral L1 hypomethyla-
tion was a prognostic parameter, L1 methylation status
did not show any prognostic difference of survival in pa-
tients with AGC of p53 expression group 3. This finding
indicates that application of L1 methylation status as a
Table 1 p53 expression status and its association with clinicopathological features (Continued)
p53 expression group P value P value
(1 vs 0, 2,
and 3)
0 1 2 3
Perineural invasion 0.051 0.305
Absent 56 (11.4) 78 (15.9) 42 (8.6) 44 (9.0)
Present 47 (9.6) 108 (2.0) 42 (8.6) 73 (14.9)
MSI < 0.001 < 0.001
Stable 86 (17.6) 128 (2.4) 71 (14.5) 98 (20.0)
Low 14 (2.9) 13 (2.7) 5 (1.0) 16 (3.3)
High 3 (0.6) 45 (9.2) 8 (1.6) 3 (0.6)
EBV < 0.001 < 0.001
Absent 102 (20.8) 164 (33.5) 74 (15.1) 114 (23.3)
Present 1 (0.2) 22 (4.5) 10 (2.0) 3 (0.6)
Percentages in parenthesis
MSI microsatellite instability, EBV Epstein–Barr virus
Fig. 2 Kaplan–Meier curve with a log-rank test for p53 expression status. a p53 expression group 1 versus group 0 in overall survival (OS) and
disease-free survival (DFS), b All AGC samples were divided into two categories (p53 expression group 1 versus group 0, 2, and 3) for survival
analysis of overall survival (OS) and disease-free survival (DFS)
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prognostic biomarker needs to be accompanied with p53
immunohistochemistry.
In the present study, we did not perform sequencing
analysis of TP53 mutation and instead used p53 expres-
sion status (determined by immunohistochemistry) as sur-
rogates for TP53 mutation status. In a previous study in
which we analyzed colorectal cancer tissue for their TP53
mutation and expression statuses using next-generation
sequencing and immunohistochemistry, respectively, and
correlated them, we found that p53 expression groups
differed significantly in the frequency and type of TP53
mutations; nonsynonymous single-nucleotide variant rate
was 80%, 12%, and 2% in p53 group 3, 2, and 1, respect-
ively, whereas p53 group 0 was featured with stop-gain
mutations (38%) and indels (15%) [18]. Through the
grouping of p53 immunohistochemistry, it was possible to
predict what percentage of variants are likely to be and
what kind of mutation will be present, but it is not correct
to predict that group 1 has no mutation or group 0 does
not have wild type. Other researchers also have reported
that a strong correlation exists between gene mutation
and p53 expression group [19, 20]. Therefore, we deduced
that the immunohistochemical status of p53 is a represen-
tative of its mutation status. However, limitation of the
utilization as p53 expression status as surrogates for TP53
mutation status is as follows: with immunohistochemical
finding, it cannot be predicted whether TP53 is wild type
or mutated, but the probability of mutation can be pre-
dicted based on grouping of p53 expression.
In our study, three expression vectors encoding
DNA-binding domain p53 mutants (V143A, R175H, and
R249S) were transfected to explore whether p53 mutants
differentially influence L1 activity and methylation.
L1-transfected AGS cells showed different L1 activity
and methylation level depending on the type of p53 mu-
tants. Mutant p53 R175H and R249S are among the p53
hotspot mutants and these arginine residues (Arg-175
and Arg-249) play a role in maintaining the structural
integrity of the DNA binding surface [21]. Although mu-
tant p53 V143A is not one of the p53 hotspot mutants,
valine residue (Val-143) is located in the hydrophobic
core of the beta-sandwich region and V143A mutant
leads to destabilization of the three-dimensional structure
and temperature sensitivity of p53 binding to many re-
sponse elements [21]. Furthermore, mutant p53 R175H
and R249S are known to lose their DNA binding affinity
to GADD45 DNA, whereas mutant p53 V143A retains its
binding affinity to GADD45 DNA [22]. In the present
study, mutant p53 R175H shows higher L1 activity and
lower L1 methylation level compared with other mutant
p53 V143A and R249S.
In the present study, we found that tumoral L1 hypo-
methylation did not have prognostic implications in
patients with gastric cancer of p53 group 3. This finding
suggests that endogenous factors of tumor cells might
have an influence on prognostic implications of tumoral
L1 hypomethylation and that p53 immunohistochemis-
try is required for the application of L1 methylation
status as a prognostic parameter in AGC. Besides gastric
cancer, several tissue types of human cancer have shown
the association between tumoral L1 hypomethylation
and shortened survival time of patients, including esopha-
geal squamous cell carcinoma, lung cancer, colorectal
cancer, and intrahepatic cholangiocarcinoma [23–27].
These tissue types of human cancer are known to have a
high frequency of TP53 mutation. However, limited infor-
mation is available regarding the interaction of TP53 in
the relationship between tumoral L1 hypomethylation and
shortened survival time of tumor patients. Although
Morikawa et al.’s study has demonstrated a difference of
L1 methylation level between CRCs of p53 group 0 and 1
and CRCs of group 2 and 3, multivariate analysis did not
reveal such a relationship [28]. Morikawa et al.’s study did
not separate CRCs of p53 group 0 and group 1 and in-
stead grouped together into a p53-negative group, which
might underestimate the relationship between L1 methy-
lation level and p53 expression group. Nevertheless, L1
methylation and p53 expression statuses were found to be
independently associated with colorectal cancer outcome.
However, in the present study, p53 expression status was
not an independent prognostic factor in patients with
AGC, while L1 methylation status was an independent
prognostic parameter.
In a previous study in which Kawakami et al. ana-
lyzed microsatellite-stable and CpG island methylator
phenotype-negative colorectal cancers (n = 131) for
their L1 methylation status and investigated the influence
of adjuvant fluopyrimidines on the prognostic value of L1
Table 2 Multivariate survival analysis
Variables Hazard ratio 95% CI P value
Overall survival
pTNM 1.955 1.429–2.673 < 0.001
Lymphatic invasion 1.719 1.126–2.624 0.012
Venous invasion 1.349 0.936–1.946 0.109
Perineural invasion 1.228 0.862–1.750 0.255
p53 expression status 0.877 0.599–1.285 0.501
L1 methylation 0.566 0.381–0.841 0.005
Disease-free survival
pTNM 1.963 1.435–2.684 < 0.001
Lymphatic invasion 1.758 1.149–2.689 0.009
Venous invasion 1.329 0.918–1.924 0.132
Perineural invasion 1.145 0.806–1.628 0.449
p53 expression status 0.859 0.587–1.255 0.432
L1 methylation 0.979 0.962–0.996 0.015
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methylation status [29], CRC patients with low L1 methy-
lation status who were treated with adjuvant fluoropyrimi-
dines showed better survival than that of patients with
low methylation status, treated with surgery alone. Such a
survival benefit from adjuvant fluoropyrimidines was not
found for CRC patients with high L1 methylation status.
Thus, a question might be raised upon whether adjuvant
chemotherapy might exert an influence on the prognostic
value of L1 methylation status in AGC patients of the
present study. When OS and DFS were analyzed for their
associations with L1 methylation status in four p53 ex-
pression groups, the tendency of low L1 methylation
status toward worse survival was observed in groups 0, 1,
and 2 regardless of whether the patients received adjuvant
chemotherapy or not (Additional file 3: Figure S3). These
results suggest that adjuvant chemotherapy might not in-
fluence the prognostic value of L1 methylation status in
patients with AGC. For group 3, L1 methylation status
was not associated with survival in patients treated with
adjuvant chemotherapy or surgery alone.
Conclusions
Taken together, we have found that TP53 mutation status
affects L1 methylation level and retrotransposon activity
in tumor cells and that L1 methylation level was different
in AGCs according to p53 expression status. Our findings
suggest that application of tumoral L1 hypomethylation as
a prognostic parameter to gastric cancer should be accom-
panied by p53 immunohistochemistry although tumoral
Fig. 3 Kaplan–Meier survival curves were compared between two groups using a log-rank test to determine difference of patient survival
according to L1 methylation status in each p53 expression group. a All AGC samples were included. b AGC samples with negative p53
expression (intensity group 0). c AGC samples with p53 expression group 1. d AGC samples with p53 expression group 2. e AGC samples with
p53 expression group 3. f All AGC samples except p53 expression group 1 (group 0, 2, and 3)
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L1 hypomethylation was an independent prognostic par-
ameter heralding poor prognosis.
Methods
Patient and tissue specimens
Four hundred ninety formalin-fixed paraffin-embedded
(FFPE) samples of AGC, defined by gastric cancer with
the invasive depth of at least the muscularis propria
(pT2–pT4 according to the 7th cancer staging system of
the American Joint Committee on Cancer), were col-
lected from the pathological archive of Seoul National
University Hospital. All samples were selected from
patients who received resection of AGC between January
2007 and December 2008. Clinical data were obtained
from the electronic medical record retrospectively. The
age of patients ranged from 23 to 86 (mean age of 61).
Male to female ratio was 2.10:1. This study was approved
by the Institutional Review Board of Seoul National
University Hospital, which waived the requirements to
obtain informed patient consent.
Detection of molecular subtypes
All AGC samples were tested for MSI and EBV infection.
For MSI status, 5-marker scoring panel (BAT25, BAT26,
D2S123, D5S345, and D17250) was applied. MSI-H was
defined when instability was detected in greater than or
equal to 40% of markers. Other cases were categorized as
MSI-negative. EBV-positive AGC was detected via in situ
hybridization with RNAscope FFPE assay kit (# 300039,
ACDbio Inc., Hayward, CA, USA) that target EBER1.
Extraction of genomic DNA from archival tissue samples
FFPE blocks containing each patient sample were cut
with 10-μm thickness and attached to glass slides. Slides
were soaked into xylene followed by air dry. Tumor
areas of each slide were traced from tumor areas marked
from its H&E counterpart and microdissected with a
razor blade into 50 μL of lysis buffer including 10% pro-
teinase K (P4850, Sigma-Aldrich, St. Louis, MO, USA).
Dissected tissues were incubated at 56 °C for at least 24
h. Proteinase K was inactivated by heat block at 95 °C
for 30 min.
Tissue microarray (TMA) and immunohistochemistry
Through microscopic examination, representative areas
that contain a considerable amount of tumor were se-
lected and core tissues (2mm in diameter) were extracted
for each AGC FFPE sample and constructed into TMA
blocks. For immunohistochemical staining, sections of
TMA were immunostained after antigen retrieval. Primary
antibody for anti-p53 (clone DO-7, DAKO, Santa Barbara,
CA, USA) was stained at a concentration of 1:1000. The
proportion of tumor cells with moderate/strong nuclear
staining for TP53 was estimated by light microscopic
examination of two tissue cores (2mm in diameter) for
each patient sample. Tumors were defined as p53 group 3
Fig. 4 L1 expression level and methylation level in TP53-transfected AGS gastric cancer cell line. a Green fluorescence protein observed by
fluorescence microscope from TP53-transfected AGS (scale bar 100 μm). b EGFP protein expression levels from TP53-transfected AGS. c
Quantification of EGFP intensity by western blot from TP53-transfected AGS. d Mean methylation levels of the four L1 CpG sites for AGS cell line
expressing wild type and mutant type TP53 (V143A, R175H, and R249S). (ns P > 0.05, *P < 0.05, **P < 0.01)
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and 2 when > 90% and 90–50% of tumor cells showed
moderate/strong nuclear staining, respectively. p53 group
1 denoted samples with moderate/strong nuclear staining
in less than 50% of tumor cells or samples with weak nu-
clear staining. p53 negativity (p53 group 0) was defined as
no staining of tumor cells which was contrasted with weak
nuclear staining of interstitial lymphocytes (Additional
file 4: Figure S4).
Cell culture and growth media
The human gastric cancer cell line AGS was purchased
from Korean Cell Line Bank (KCLB# 21739, Korean Cell
Line Bank, Seoul, Korea) and was grown in RPMI-1640
(LM 011–01, Welgene Co., Daegu, Korea) supplemented
with 10% heat-inactivated FBS (Fetal bovine serum)
(26140–079, Gibco, Grand Island, NY, USA), 100 U/ml
penicillin, and 100 μg/ml streptomycin (15070–063, Gibco).
Plasmid DNA used in transfection assay
Plasmids encoding wild type TP53 (#16434, Addgene,
Watertown, MA, USA) and mutant type TP53 (V143A,
R175H, and R249S) (#16435, #16436, and #16438,
Addgene) under the control of the CMV promoter were
purchased from Addgene. The pLRE3-mEGFP1 (mono-
meric enhanced green fluorescent protein) plasmid, encod-
ing a retrotransposition-competent L1, and pJM111-
LRE3-mEGFP1, encoding a retrotransposition-defective L1,
were generous gifts from Dr. Moran (University of Michigan
Medical school). pCMV6-Entry (PS100001, ORIGENE,
Rockville, MD, USA) (that includes G418-resistance gene)
plasmid was used as a control DNA. Schematic diagram of
the pLRE3-mEGFP1 construct and rationale of the
L1-retrotransposition assay is depicted in Additional file 5:
Figure S5.
p53 knockdown using shRNA lentiviral plasmid
Plasmids expressing control shRNA (short hairpin RNA)
(#H1(shRNA-Ctr)-RB) and shRNA against human TP53
(#LVP343-RB) were purchased from GenTarget Inc. (San
Diego, CA, USA). The plasmid contains RFP (Red Fluor-
escence Protein)-Bsd (Blasticidin) dual selection marker
(15,205, Sigma-Aldrich). AGS cells were transduced with
pre-made lentiviral plasmid containing control shRNA
and TP53 shRNA. Three days after transduction, cells
were incubated with RPMI-1640 complete medium con-
taining 6 μg/ml blasticidin (RPMI-Bsd). For generating
cells stably expressing control shRNA and TP53 shRNA,
single cells expressing RFP were sorted by BD FACS
(Fluorescence-activated cell sorter) Aria II into individ-
ual wells of 96-well plates. Several single colonies were
screened by light microscope, selected, and transferred
to individual wells in 48-well dishes and expanded in
RPMI-Bsd media. Stable knockdown of TP53 expression
was confirmed by western blot.
Generation of stable cell line (transfection and selection
of cells)
AGS cells were transfected with the pLRE3-mEGFP1
and pJM111-LRE3-mEGFP1 construct by electropor-
ation (Nepa Gene Co., Ichikawa city, Japan) and selected
for puromycin-resistant cells by growth in RPMI-1640
complete medium containing 0.3 μg/ml puromycin
(RPMI-Puro) (P8833, Sigma-Aldrich). After complete
antibiotic selection, the cells were trypsinized and plated
at low density in 6-well plates. EGFP-expressing clones
were observed by fluorescence microscopy. Several fluor-
escent colonies were selected, transferred to individual
wells in 6-well dishes, and expanded in RPMI-Puro. AGS
cells stably expressing L1 were transduced with a lentiviral
plasmid expressing TP53 shRNA and single cells were
sorted by BD FACS (Fluorescence-activated cell sorter)
Aria II. Wild type and three types of mutant TP53 were
then transfected into AGS stably expressing L1 and p53
shRNA. G418 (A1720, Sigma-Aldrich) selection and con-
firmation of transfection were done as described above.
The colonies were screened for their presence by western
blot analysis.
Western blot analysis
Cells were lysed with RIPA buffer supplemented with
protease inhibitor cocktail (11,836,153,001, Complete
Mini, Roche, Mannheim, Germany) and phosphatase in-
hibitor cocktail (04906845001, PhosSTOP EASYpack,
Roche). Cell debris were then removed by centrifugation
at 4 °C. After centrifugation, protein concentrations were
measured with Pierce BCA Protein Assay Kit (23,225,
Thermo Fisher Scientific, Rockford, IL, USA). For western
blotting, 30 μg of protein lysates from each established cell
line were separated by 8~10% SDS-polyacrylamide gel
electrophoresis (PAGE), transferred onto nitrocellulose
membranes (IPVH00010, Millipore, Bedford, MA, USA),
blocked at room temperature for 1 h with 5% skim milk,
and incubated at 4 °C overnight with the following
primary antibodies: p53 (1:1000, sc-126, Santa Cruz
Biotechnology, CA, USA), β-actin (1:1000, sc-47,778,
Santa Cruz Biotechnology), and EGFP (1:1000, ab184601,
Abcam, Cambridge, UK). After three 15-min washes with
Tris-buffered saline containing 0.1% Tween 20, the blots
were incubated at room temperature for 1 h with horse-
radish peroxidase-conjugated secondary antibody: goat
anti-Mouse IgG(H+L)-HRP (1:4000, #SA001–500, Gen-
DEPOT, Barker, TX, USA). Proteins were detected using
chemiluminescent reagent, ECL solution (#W6002, Biose-
sang, Gyeonggi, Korea).
DNA preparation and bisulfite conversion
Genomic DNA was extracted from cell lines using the
QIAamp DNA mini kit (51,306, Qiagen, Hilden, Germany).
DNA samples were then digested in 20-μl reaction volumes
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with 15U of HindIII (1060A, Takara Shuzo Co., Kyoto,
Japan) for 1 h at 37 °C prior to bisulfite modification.
Bisulfite modification was performed using the Zymo
EZ DNA methylation Kit (D5002, Zymo Research, Irvine,
CA, USA) with 500 ng of digested genomic DNA accord-
ing to the manufacturer’s protocol.
MethyLight assay and pyrosequencing methylation assay
After bisulfite modification, Alu-based MethyLight con-
trol reaction, a CpG-independent and bisulfite-specific
control reaction, was performed to measure input DNA
(bisulfite-modified DNA) [30]. We determined the thresh-
old cycle (C(t) value) of this reaction in which the Alu
reaction fluorescence was detected. To keep the C(t) value
of bisulfite-modified DNA samples in the range of 18 to
20, distilled water was added to dilute bisulfite-modified
DNA samples with C(t) values lower than 18. The sodium
bisulfite-modified DNA samples were amplified with the
same oligonucleotide primers which were designed against
a consensus L1 sequence by the Issa group for pyrose-
quencing [31]. Pyrosequencing methylation assay was
performed as described previously [32].
Statistical analysis
All statistical analysis was performed by R (version
3.5.1). The correlation between categorical variables was
performed with chi-square test when all categories were
more than 5. If at least one category was equal to or less
than 5, Fisher exact test was applied. Correlation between
continuous variables and two categories were measured
by Student t test. ANOVA was performed between vari-
ables that included more than two categories. Mann–
Whitney U test (Wilcoxon rank-sum test) was applied
when the relationship between continuous variables and
variables with more than two categories was measured.
Univariate survival was determined by Kaplan–Meier
curve with a log-rank test. To calculate multivariate sur-
vival, Cox regression model was applied. P value of < 0.05
was considered as significant.
Additional files
Additional file 1: Figure S1. Forest plot displaying relationships
between L1 methylation level and clinicopathological characteristics.
(TIF 400 kb)
Additional file 2: Figure S2. Evaluation of transfection by western blot
analysis. p53 protein expression level in AGS transfected with wild type
or mutant types of TP53 by western blot. (TIF 324 kb)
Additional file 3: Figure S3. Comparative analyses of overall survival
and disease-free survival in four p53 expression groups of gastric cancers
according to L1 methylation status with separation into adjuvant
chemotherapy-treated and nontreated groups. (TIF 4730 kb)
Additional file 4: FigureS4. Classification of p53 expression status by
immunohistochemical staining. (A) p53 negativity (group 0). (B)
Moderate/strong nuclear staining in less than 50% of tumor cells or
samples with weak nuclear staining (group 1). (C) 90–50% of tumor cells
showed moderate/strong nuclear staining (group 2). (D) > 90% of tumor
cells showed moderate/strong nuclear staining (group 3). (TIF 4060 kb)
Additional file 5: Figure S5. Schematic diagram of the pLRE3-mEGFP1
construct (left) and rationale of the L1-retrotransposition assay (right). The
EGFP retrotransposition reporter cassette is cloned into the 3′UTR of L1 in
the antisense orientation. The cassette consists of the CMV promoter
(pCMV), the TK poly(A) signal (pA) and the EGFP gene interrupted by a
sense orientation intron (intron) with the splice donor (SD) and splice
acceptor (SA). (TIF 335 kb)
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